The Law Offices of Frank R. Cruz announces an investigation of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: ...

The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or ...

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Beta Bionics, Inc. (“Beta Bionics” or ...

The downgrade comes after the Irvine-based medical device company reported preliminary fourth quarter results.

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (“Beta Bionics” or the ...

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 ...

The projected fair value for Beta Bionics is US$20.69 based on 2 Stage Free Cash Flow to Equity. Current share price of US$17 ...

Net sales of $23.2 million, up 54% compared to $15.0 million in the second quarter of 2024. Gross margin of 53.8%, up 7 basis points compared to 53.7% in the second quarter of 2024. Installed customer ...

Beta Bionics reported Q4 2025 sales growth, but analysts raised concerns about valuation and slower patient starts.

Beta Bionics, Inc. has announced that it will release its financial results for the second quarter of 2025 after the markets close on July 29, 2025. Following the release, company management will host ...

IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release ...

IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (BBNX), a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its ...